As of Oct. 16, total U.S. shipments of COVID-19 molecular diagnostic tests have topped the 200 million mark, according to the AdvaMed COVID-19 Diagnostic Supply Registry (Registry). On average, diagnostics companies are shipping, over 1.4 million molecular tests every day. Registry data also show that approximately 121 million COVID-19 molecular tests have been administered. The AdvaMed Registry Since the pandemic began, federal and state government response actions have been impaired by the lack of widely available national data on COVID-19 testing and supplies has been a problem impairing since the pandemic began. On July 21, with that problem in mind, the Advanced Medical Technology Association (AdvaMed) launched a national COVID-19 diagnostic supply registry compiling information from diagnostic companies with publicly available daily test data.  The Registry provides weekly state and national updates on the number of molecular and serology (antibody) tests shipped in the U.S. AdvaMed and AdvaMedDx, the association’s diagnostics division, developed the Registry in partnership with 13 commercial diagnostics manufacturers: Abbott; Becton Dickinson; bioMérieux; Bio-Rad; Beckman Coulter; Cepheid; Hologic; Ortho Clinical Diagnostics; QIAGEN; Roche Diagnostics; Sekisui Diagnostics; Siemens Healthineers; and Thermo Fisher Scientific. Key Registry Findings According to the Registry, as of Oct. 16: The 13 Registry participants have shipped […]